Cardiogen

Overview

Cardiogen is a short synthetic tetrapeptide with the sequence Ala-Glu-Asp-Arg (commonly abbreviated AEDR). It belongs to the family of "short peptide bioregulators" developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, and it is marketed as a heart/myocardium-targeted compound.

The chemistry is well-defined and independently verifiable: PubChem (CID 11583989) gives the molecular formula C18H31N7O9 and a molecular weight of 489.5 g/mol for the Ala-Glu-Asp-Arg sequence. The name "Cardiogen" for AEDR, together with a proposed role in "regulation of cardiovascular system function," appears in a peer-reviewed systematic review (Khavinson et al., Molecules 2021).

The evidence behind the biological claims, however, is thin and preclinical. What can actually be verified is limited to in-vitro binding assays — AEDR is grouped with peptides shown to bind histone proteins and to modulate DNA hydrolysis in cell-free systems — plus the broad, hypothesis-level Khavinson model in which such 2–4 residue peptides enter cell nuclei and influence tissue-specific gene expression. The specific cardiac-efficacy claims (cardiomyocyte differentiation, connexin-43, recovery after ischemia) are asserted by vendors and secondary sources but could not be confirmed: no PubMed hits for Cardiogen/AEDR-specific cardiac studies were found. There is no verified human clinical evidence.

This is the typical Khavinson-bioregulator picture: older, mostly-Russian, largely mechanistic and preclinical, with little to no independent Western replication. Cardiogen is often grouped with other Khavinson short peptides such as Epitalon and Thymalin; the gap between confident mechanistic language and rigorous human evidence is the central thing to understand.

Chemistry and structure

Cardiogen is a linear tetrapeptide (four amino acids):

Ala-Glu-Asp-Arg (H-Ala-Glu-Asp-Arg-OH; abbreviated AEDR)

The formula, weight, and sequence are confirmed via the PubChem record (CID 11583989). No CAS Registry Number was present in PubChem, and vendors list it as unavailable, so the CAS number is treated as not established.

Mechanism of action

The mechanisms attributed to Cardiogen are best read as hypotheses derived from the general Khavinson framework, with a narrow layer of in-vitro binding data underneath. None establishes a physiological mode of action in humans.

• Nuclear entry and gene regulation. As a Khavinson short peptide, AEDR is proposed to penetrate cell nuclei and interact with DNA promoter regions/histones to modulate tissue-specific (cardiac) gene expression. [Hypothesis] — this is the core bioregulator model; it is framework-level and not proven for cardiac outcomes. (Khavinson et al., Molecules 2021.)
• Histone binding. AEDR (together with EDR, AEDG, AEDL, KEDW, KEDG) was reported to bind histone proteins H1, H2b, H3 and H4 in a fluorescence-quenching binding assay using wheat histones. [In vitro] (Khavinson et al., Molecules 2021, PMC8619776.)
• DNA-hydrolysis modulation. AEDR was reported to inhibit or stimulate hydrolysis of lambda bacteriophage DNA in a cell-free biochemical assay. [In vitro] (same review.)
• Cardiac functional effects. Improved cardiomyocyte differentiation/metabolism, connexin-43 and troponin expression, and recovery after ischemia/MI are attributed to Cardiogen. [Hypothesis] — asserted by vendors/secondary sources; specific controlled cardiac studies were not verified on PubMed.

Research and evidence

Human evidence. There are no well-established human clinical trials. No specific peer-reviewed human study of Cardiogen (AEDR) could be located on PubMed. Vendor and secondary sources refer vaguely to "Russian and Eastern European studies," but no specific study, journal, or PMID was verifiable. Human efficacy and safety should be treated as unestablished.

Status and regulation

Cardiogen is not FDA- or EMA-approved for any indication, and is not an approved medicine anywhere we could verify. It is sold only as a "for laboratory/research use only" reagent — not a dietary supplement and not a licensed drug. Secondary sources indicate it is not scheduled under the US Controlled Substances Act, but "no specific ban" is not affirmative permission: any intended human use would make it an unauthorised/unapproved medicine. No WADA prohibited-status or class code is asserted by any source we found, so its sport-doping status is unknown and must not be inferred. This is not medical or legal advice; verify your local jurisdiction (dated 2026-07).

Safety

• The human safety profile of Cardiogen is poorly characterized; a lack of reported adverse events reflects a lack of rigorous study, not a demonstration of safety.
• No verified data exist on human pharmacokinetics (half-life, bioavailability, route), repeated dosing, or long-term exposure. [Not established]
• Material sold as "Cardiogen" is a research reagent; its identity, purity, and contaminant profile cannot be assumed to be controlled.
• Because it is handled as an injectable research peptide in unregulated contexts, the usual risks of non-sterile injectable products also apply.

Legal status

Cardiogen is classified and sold as a research reagent ("for laboratory research use only"), not as a medicine or dietary supplement. It has no marketing authorisation from the FDA, EMA, or any regulator we could verify. The absence of a specific scheduling ban is not permission for human use — a compound becomes an unauthorised medicine the moment it is intended for human use. Sport-anti-doping status (WADA) is a separate axis from legality and is unknown for this peptide; do not assume it is permitted in competition. This is not legal advice; laws differ by country and change over time — check your own jurisdiction (dated 2026-07).

How it compares

Cardiogen sits alongside other Khavinson-school short peptide bioregulators, which share the same evidence pattern: verifiable chemistry, hypothesis-level gene-regulation models, and sparse independent human data.

For a mechanistically distinct, more clinically studied cardiac/mitochondrial peptide, see SS-31 (elamipretide) — its human trials target defined diseases, unlike Cardiogen, which has no verifiable human data.

Common misconceptions

• "Cardiogen is a proven heart medicine." It is not. The cardiac-efficacy claims are vendor/secondary and could not be confirmed on PubMed; there is no verified human trial.
• "It's been shown to regenerate heart tissue after a heart attack." No controlled study demonstrating ischemia/MI recovery, connexin-43, or cardiomyocyte effects could be verified. These are [Hypothesis]-level assertions.
• "The gene-regulation mechanism is established science." The nuclear-entry, DNA/histone gene-regulation model is a [Hypothesis] from the Khavinson group; only narrow in-vitro binding assays are verifiable.
• "It's legal, so it's safe to take." Absence of a specific ban is not permission or a safety finding. Cardiogen is a research reagent with unestablished human safety, and intended human use would make it an unapproved medicine.